Silexion Therapeutics
SLXN
7 hedge funds and large institutions have $42.8K invested in Silexion Therapeutics in 2026 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 3 closing their positions.
143% more capital inflows, than outflows
Capital inflows: $101K | Capital outflows: $41.7K
4.07% more ownership
Funds ownership: 1.1% → 5.16% (+4.1%)
0% more funds holding
Funds holding: 7 → 7 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HRT Financial
New York
|
+$92K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$8.2K |
| 3 |
BPI
BFC Planning, Inc.
Cedar Rapids,
Iowa
|
+$803 |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$459 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$26.8K |
| 2 |
Two Sigma Securities
New York
|
-$14.9K |
| 3 |
Jones Financial Companies
Des Peres,
Missouri
|
-$32 |
SLXN Hedge Fund Activity: Q2 2026 in Review
7 of the 8,378 institutional investors tracked by Wall St. Rank reported a position in Silexion Therapeutics (SLXN) for Q2 2026, worth a combined $42.8K — down 8.4% from $46.7K a quarter earlier.
Fund positioning in SLXN was balanced in Q2 2026: 3 funds opened new positions, 3 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was HRT Financial, opening a new position worth an estimated $92K. The largest seller was Citadel Advisors, exiting entirely with an estimated $26.8K sold.
- 7 institutional investors held Silexion Therapeutics (SLXN) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $42.8K of Silexion Therapeutics stock for Q2 2026, down 8.4% quarter-over-quarter.
- 3 funds opened new Silexion Therapeutics positions in Q2 2026 and 3 closed out, a net change of 0 holders.
- The largest Silexion Therapeutics buyer in Q2 2026 was HRT Financial, an estimated $92K added.
- The largest Silexion Therapeutics seller in Q2 2026 was Citadel Advisors, an estimated $26.8K sold.
Based on aggregated 13F filings for Q2 2026.